ArticleScientific reports2017
The diagnostic and prognostic value of interleukin-6 in patients with soft tissue sarcomas.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Beyond Prosthetic Valve Infection: Anchoring Bias Delaying the Diagnosis of Synovial Sarcoma.Cureus · 2026Article
- Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy.International journal of cancer · 2025Review
- Article
- Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Emergency myelopoiesis in solid cancers.British journal of haematology · 2024Review
- C‑reactive protein and related predictors in soft tissue sarcoma (Review).Molecular and clinical oncology · 2024Review
- Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications.Experimental & molecular medicine · 2023Article
- Interleukin-6 initiates muscle- and adipose tissue wasting in a novel C57BL/6 model of cancer-associated cachexia.Journal of cachexia, sarcopenia and muscle · 2023Article
- Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients.Frontiers in pharmacology · 2023Article
- Review
- Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.BMC cancer · 2022Article
- Review
- Evaluation of hepatic enzymes activities in COVID-19 patients.International immunopharmacology · 2021Article
- Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.Cancers · 2021Review
- Sarcoma treatment in the era of molecular medicine.EMBO molecular medicine · 2020Review
- Anti-tumour effect of tocilizumab for osteosarcoma cell lines.Bone & joint research · 2020Article
- Article
- Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART.Journal of inflammation (London, England) · 2020Article
- Negative Impact of Wound Complications on Oncologic Outcome of Soft Tissue Sarcomas of the Chest Wall.Cancers · 2019Article
- Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas.Cancer biomarkers : section A of Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of systemic inflammation has been reported to be associated with poor prognosis in patients with soft tissue sarcoma (STS). The cytokine interleukin-6 (IL-6) has pleiotropic effects on various cell types in the tumor microenvironment. The aim of the present study was to determine whether serum IL-6 levels could be useful to assume the differentiation of benign soft tissue tumors from STS and to investigate the possible value of IL-6 for survival and oncological events in patients with STS. The medical records of 99 patients who underwent surgical resection were retrospectively reviewed. Serum IL-6 levels (median: 9.04 pg/ml) in patients with STS were statistically higher than those (3.31 pg/ml) in patients with benign soft tissue tumors. Our analyses confirmed that tumor size and IL-6 level were significant predictors of STS diagnosis. Next, we examined the relationship between IL-6 levels and survival in the 59 patients with STS. C-reactive protein levels, hemoglobin levels, and tumor grade were strongly correlated with IL-6 levels. Tumor grade and IL-6 level remained significant factors for survival and event-free survival. We suggest that measurement of IL-6 levels may be a useful method for identifying patients who are at a high risk of STS and tumor-related death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.